how big is Biogen Pharma?

As of Jun 06, Biogen Pharmachem Industries Ltd has a market capitalization of 61.34 Cr, classifying it as a Micro Cap company, with recent net sales of 0.00 Cr and a net profit of -0.29 Cr. Shareholder's funds are valued at 56.52 Cr, and total assets amount to 56.82 Cr.

Market Cap: As of Jun 06, Biogen Pharmachem Industries Ltd has a market capitalization of 61.34 Cr, which classifies it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, the sum of Net Sales is 0.00 Cr, and the sum of Net Profit is -0.29 Cr. This data is presented on a Standalone basis.<BR><BR>Balance Sheet Snapshot: This is Standalone data for the reporting period ending in Mar'24. The Shareholder's Funds are valued at 56.52 Cr, and the Total Assets amount to 56.82 Cr.

What does Biogen Pharma do?

Biogen Pharmachem Industries Ltd is a Micro Cap company engaged in trading shares, securities, and commodities within the Non Banking Financial Company (NBFC) sector. It was incorporated in 1995 and reported a net profit of 1 Cr for the quarter ending March 2025.

Overview:<BR>Biogen Pharmachem Industries Ltd is engaged in the business of trading in shares and securities, commodities, and other goods, operating within the Non Banking Financial Company (NBFC) industry and categorized as a Micro Cap.<BR><BR>History:<BR>The company was incorporated in July 1995 as Wellworth Overseas Limited and underwent several name changes, becoming Sun Techno Overseas Limited in August 2011 and finally Biogen Pharmachem Industries Limited on March 24, 2021. The latest reported quarter for sales and profit is March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: 1 Cr (Quarterly Results - Mar 2025)<BR>Market-cap value: Rs 62 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A<BR>Industry P/E: 30<BR>Dividend Yield: 0.00%<BR>Debt Equity: -0.10<BR>Return on Equity: -0.51%<BR>Price to Book: 1.09<BR><BR>Contact Details:<BR>Address: Shop No 8 First Floor, Makers 1 Building Jawahar Road Rajkot Gujarat : 360001<BR>Phone: 91-79-27498832<BR>Email: suntechnooverseas@gmail.com<BR>Website: http://www.biogenpharma.shop

Who are in the management team of Biogen Pharma?

As of March 2022, the management team of Biogen Pharma includes Niraj Vaghela (Whole Time Director & CFO), Chandrakant Govingbhai Parmar, Manjulaben Parmar (both Independent Directors), Khushboo Khandelwal (Company Secretary & Compliance Officer), and Directors Harshadkumar Rathod, Narendrakumar Vaniya, and Komalben Chauhan. They oversee the company's operations and governance.

As of March 2022, the management team of Biogen Pharma includes the following individuals:<BR><BR>1. Niraj Vaghela - Whole Time Director & CFO<BR>2. Chandrakant Govingbhai Parmar - Independent Director<BR>3. Manjulaben Parmar - Independent Director<BR>4. Khushboo Khandelwal - Company Secretary & Compliance Officer<BR>5. Harshadkumar Rathod - Director<BR>6. Narendrakumar Vaniya - Director<BR>7. Komalben Chauhan - Director<BR><BR>These individuals are responsible for overseeing the company's operations and governance.

Has Biogen Pharma declared dividend?

No Dividend History Available

Who are the peers of the Biogen Pharma?

Biogen Pharma's peers include Bajaj Finance, Jio Financial, Cholaman.Inv.&Fn, Shriram Finance, Muthoot Finance, and others. In terms of management risk, growth, and capital structure, Biogen Pharma has good ratings, with a 1-year return of -14.78%, better than Arnold Holdings but worse than BAMPSL Sec.

Peers: The peers of Biogen Pharma are Bajaj Finance, Jio Financial, Cholaman.Inv.&Fn, Shriram Finance, Muthoot Finance, ISL Consulting, Ladderup Finance, Arnold Holdings, BAMPSL Sec., and BSEL ALGO.<BR><BR>Quality Snapshot: Excellent management risk is observed at Bajaj Finance, Cholaman.Inv.&Fn, and Muthoot Finance, while Average management risk is found at Jio Financial. Good management risk is noted at Shriram Finance, and the rest have Below Average management risk, including ISL Consulting, Ladderup Finance, Arnold Holdings, Biogen Pharma, BAMPSL Sec., and BSEL ALGO. For Growth, Excellent growth is seen at Jio Financial, Arnold Holdings, and BAMPSL Sec., while Good growth is noted at Bajaj Finance and Cholaman.Inv.&Fn, with Average growth at Muthoot Finance and Shriram Finance, and the rest showing Below Average growth. In terms of Capital Structure, Excellent capital structure is found at Bajaj Finance, Jio Financial, Muthoot Finance, Shriram Finance, ISL Consulting, Ladderup Finance, Arnold Holdings, and BAMPSL Sec., while Good capital structure is noted at Biogen Pharma, and the rest have Below Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is BAMPSL Sec. at 103.62%, while the lowest is Arnold Holdings at -47.98%. Biogen Pharma's 1-year return of -14.78% is better than Arnold Holdings but worse than BAMPSL Sec. Additionally, ISL Consulting, Arnold Holdings, and BSEL ALGO have negative six-month returns.

Is Biogen Pharma overvalued or undervalued?

As of May 26, 2025, Biogen Pharma is considered very expensive and overvalued due to a negative PE ratio of -61.34, an EV to EBIT ratio of 55.88, and a low ROE of -0.51%, despite a 357.14% stock increase over five years, which underperformed against the Sensex's 7.62% return in the last year.

As of 26 May 2025, the valuation grade for Biogen Pharma has moved from risky to very expensive. The company is currently overvalued, as indicated by its PE ratio of -61.34, an EV to EBIT ratio of 55.88, and a Price to Book Value of 1.09. These ratios highlight significant concerns regarding profitability and valuation relative to its assets.<BR><BR>In comparison to its peers, Biogen Pharma's valuation stands out unfavorably; for instance, MMTC has a PE ratio of 119.39, while Elitecon International shows a PE of 131.08, both indicating a more favorable valuation in the market. Additionally, Biogen's return on equity (ROE) is at -0.51%, further emphasizing its struggles compared to competitors. While Biogen's stock has seen a notable increase of 357.14% over the past five years, it has underperformed against the Sensex in the last year, which returned 7.62%. This context reinforces the conclusion that Biogen Pharma is currently overvalued.

What is the technical trend for Biogen Pharma?

As of May 19, 2025, Biogen Pharma's trend is mildly bearish, indicated by daily moving averages and monthly MACD, while weekly indicators show mixed signals, leading to a moderate bearish outlook.

As of 19 May 2025, the technical trend for Biogen Pharma has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating a bearish trend and the monthly MACD showing a mildly bearish signal. Weekly indicators present a mixed picture with the MACD and KST both mildly bullish, while Bollinger Bands remain bearish. The lack of clear signals from the RSI further supports the neutral to mildly bearish outlook. Overall, the strength of the bearish trend is moderate, influenced by the recent price action and the broader market context.

Who are the top shareholders of the Biogen Pharma?

The top shareholders of Biogen Pharma are individual investors, holding 47.04% of shares, with Rama Shiva Lease Finance Private Limited as the largest public shareholder at 9.31%. There are no institutional shareholders or pledged promoter holdings.

The top shareholders of Biogen Pharma include individual investors, who collectively hold 47.04% of the shares. The highest public shareholder is Rama Shiva Lease Finance Private Limited, which holds 9.31%. There are no institutional shareholders or mutual funds currently holding shares in the company, and there are no pledged promoter holdings.

Are Biogen Pharma latest results good or bad?

Biogen Pharma's latest results show significant improvement, with a profit before tax of Rs 1.18 crore and a year-over-year net profit growth of 937.50%. However, despite these positive metrics, the stock is rated as a 'Strong Sell' by MarketsMOJO, indicating cautious market sentiment.

Biogen Pharma's latest results indicate a significant improvement in their financial performance. For the quarter ending June 2025, the company reported a profit before tax (PBT) and profit after tax (PAT) of Rs 1.18 crore, which is the highest in the last five quarters. This reflects a positive trend, especially considering the standalone net profit saw an impressive year-over-year growth of 937.50%, compared to a negative growth in the previous year.<BR><BR>Additionally, the earnings per share (EPS) reached Rs 0.02, marking another peak in the last five quarters. However, despite these positive indicators, the stock has been rated as a 'Strong Sell' by MarketsMOJO, suggesting that there is a cautious outlook in the market despite the improved financial metrics.<BR><BR>In summary, while the financial results show strong improvement and profitability, the market sentiment appears to be more reserved.

When is the next results date for Biogen Pharma?

Biogen Pharma will announce its results on November 7, 2025.

Biogen Pharma is scheduled to declare its results on November 7, 2025.

Should I buy, sell or hold Biogen Pharma?

How has been the historical performance of Biogen Pharma?

Biogen Pharma has experienced significant financial fluctuations, with net sales dropping to zero by March 2025 after a modest increase in previous years, while total expenditures rose sharply and profitability turned negative. Despite these challenges, shareholder funds increased, and cash flow from financing activities remained positive.

Answer:<BR>The historical performance of Biogen Pharma shows significant fluctuations in its financial metrics over the years.<BR><BR>Breakdown:<BR>Biogen Pharma's net sales have remained at zero from March 2023 to March 2025, following a modest increase to 2.47 crore in March 2022 from 1.62 crore in March 2021. Other operating income peaked at 2.38 crore in March 2024 but dropped to zero in March 2025. Total operating income followed a similar trend, reaching 2.16 crore in March 2022 before declining to zero by March 2025. The company faced a total expenditure of 1.13 crore in March 2025, a significant increase from 0.45 crore in March 2024, while operating profit (PBDIT) turned negative at -0.29 crore in March 2025, contrasting with a profit of 1.93 crore in March 2024. Profit before tax also fell to -0.29 crore in March 2025 from 1.93 crore in the previous year. The company's reserves have been negative, reaching -9.03 crore in March 2025, and shareholder's funds increased to 91.93 crore in March 2025 from 56.52 crore in March 2024. Cash flow from operating activities was negative at -1.00 crore in March 2025, while cash flow from financing activities showed a positive inflow of 35.00 crore. Overall, Biogen Pharma's financial performance has been marked by instability, with recent years showing a decline in sales and profitability, despite an increase in cash reserves.

Which are the latest news on Biogen Pharma?

Why is Biogen Pharma falling/rising?

As of 03-Dec, Biogen Pharmachem Industries Ltd's stock price is rising slightly to 0.75, but it has experienced significant declines of 36.44% year-to-date and 40.48% over the past year. The stock is trading below its moving averages and has seen decreased investor participation, indicating a bearish trend despite today's minor outperformance in its sector.

As of 03-Dec, Biogen Pharmachem Industries Ltd's stock price is currently rising, with a change of 0.01 (1.35%) to a current price of 0.75. Despite this increase, the stock has faced significant downward pressure over longer periods, as evidenced by its year-to-date decline of 36.44% and a one-year drop of 40.48%. <BR><BR>Today, the stock reached a new 52-week low of Rs.0.73 earlier in the day, indicating ongoing challenges. Additionally, Biogen Pharma is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically suggests a bearish trend. <BR><BR>Investor participation has also decreased, with a delivery volume of 6.55 lacs on 02 Dec, down by 2.39% compared to the 5-day average. This decline in trading volume can indicate waning interest among investors. <BR><BR>While the stock outperformed its sector by 2.14% today, the overall context of its performance suggests that the recent rise may be a temporary fluctuation amidst a broader trend of decline.